The duration of the use of imatinib mesylate is only weakly related to elevated BNP levels in chronic myeloid leukaemia patients

Hematological Oncology

Volumn 29, Issue 3, 2011, Pages 124-130

  Marcolino, Milena S ^a   Boersma, Eric ^b   Clementino, Nelma C D ^a   Nunes, Maria do Carmo P ^a,c   Barbosa, Márcia M ^c   Silva, Maria Helena C R ^a   Geleijnse, Marcel L ^b   Ribeiro, Antonio L ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Hospital Geral Socor   (Brazil)

Author keywords

BNP; Cardiotoxicity; Imatinib; Speckle tracking echocardiography

Indexed keywords

IMATINIB;

ADULT; AGED; ARTICLE; CARDIOTOXICITY; CHRONIC MYELOID LEUKEMIA; CLINICAL EVALUATION; COLOR ULTRASOUND FLOWMETRY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LIMIT OF DETECTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SIDE EFFECT; TISSUE DOPPLER IMAGING; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DRUG ADMINISTRATION SCHEDULE; ECHOCARDIOGRAPHY; FEMALE; HEART; HEART FAILURE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PIPERAZINES; PYRIMIDINES; TREATMENT OUTCOME;

EID: 80052948961     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.967     Document Type: Article

References (35)

1. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009; 27: 6041-6051.
2. Blackstein ME, Blay JY, Corless C, et al. Gastrointestinal stromal tumours: consensus statement on diagnosis and treatment. Can J Gastroenterol 2006; 20: 157-163.
3. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038-1042.
4. Gotlib J, Cools J, Malone JM 3rd, Schrier SL, Gilliland DG, Coutre SE. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood 2004; 103: 2879-2891.
5. Chintalgattu V, Patel SS, Khakoo AY. Cardiovascular effects of tyrosine kinase inhibitors used for gastrointestinal stromal tumors. Hematol Oncol Clin North Am 2009; 23: 97-107.
6. Kerkela R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006; 12: 908-916.
7. Park YH, Park HJ, Kim BS, et al. BNP as a marker of the heart failure in the treatment of imatinib mesylate. Cancer Lett 2006; 243: 16-22.
8. Breccia M, Cannella L, Frustaci A, Stefanizzi C, Levi A, Alimena G. Cardiac events in imatinib mesylate-treated chronic myeloid leukemia patients: a single institution experience. Leuk Res 2008; 32: 835-836.
9. Garcia-Alvarez A, Sitges M, Garcia-Albeniz X, Sionis A, Loma-Osorio P, Bosch X, Atypical cardiac manifestation of hypereosinophilic syndrome and reversible cardiotoxicity to imatinib. Int J Cardiol 2010; 139: e29-31.
10. Ribeiro AL, Marcolino MS, Bittencourt HN, et al. An evaluation of the cardiotoxicity of imatinib mesylate. Leuk Res 2008; 32: 1809-1814.
11. Turrisi G, Montagnani F, Grotti S, Marinozzi C, Bolognese L, Fiorentini G. Congestive heart failure during imatinib mesylate treatment. Int J Cardiol 2009; DOI: 10.1016/j.ijcard.2009.07.006
12. Atallah E, Durand JB, Kantarjian H, Cortes J. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 2007; 110: 1233-1237.
13. Verweij J, Casali PG, Kotasek D, et al. Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005. Eur J Cancer 2007; 43: 974-978.
14. Rosti G, Martinelli G, Baccarani M. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. Nat Med 2007; 13: 15.
15. Tiribelli M, Colatutto A, Marin L, et al. Brain natriuretic peptide level as marker of cardiac function in imatinib-treated chronic myeloid leukemia patients: no evidence of cardiotoxicity of imatinib therapy. Am J Hematol 2008; 83: 517-518.
16. Perik PJ, Rikhof B, de Jong FA, Verweij J, Gietema JA, van der Graaf WT. Results of plasma N-terminal pro B-type natriuretic peptide and cardiac troponin monitoring in GIST patients do not support the existence of imatinib-induced cardiotoxicity. Ann Oncol 2008; 19: 359-361.
17. Marcolino MS, Ribeiro AL, Clementino NCD, et al. The use of imatinib mesylate has no adverse effects on the heart function. Results of a pilot study in patients with chronic myeloid leukemia. Leuk Res 2010; DOI: 10.1016/j.leukres.2010.07.011
18. O'Brien S, Berman E, Borghaei H, et al., National Comprehensive Cancer Network® (NCCN). Practice Guidelines in Oncology™: Chronic Myelogenous Leukemia Version 2.2010. 2009. Available at.
19. Blay JY, Le Cesne A, Ray-Coquard I, et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol 2007; 25: 1107-1113.
20. Hehlmann R, Hochhaus A, Baccarani M. Chronic myeloid leukaemia. Lancet 2007; 370: 342-350.
21. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117: 510-526.
22. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders-DSM IV (4th edn). American Psychiatric Association: Washington, DC; 1994.
23. Bayes de Luna A. Clinical Electrocardiography: A Textbook (2nd edn). Futura Publishing Company: Armonk; 1998.
24. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18: 1440-1463.
25. Henry WL, DeMaria A, Gramiak R, et al. Report of the American Society of Echocardiography Committee on nomenclature and standards in two-dimensional echocardiography. Circulation 1980; 62: 212-217.
26. Garcia MJ, Thomas JD, Klein AL. New Doppler echocardiographic applications for the study of diastolic function. J Am Coll Cardiol 1998; 32: 865-875.
27. Nagueh SF, Middleton KJ, Kopelen HA, Zoghbi WA, Quinones MA. Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol 1997; 30: 1527-1533.
28. Yip G, Abraham T, Belohlavek M, Khandheria BK. Clinical applications of strain rate imaging. J Am Soc Echocardiogr 2003; 16: 1334-1342.
29. Serri K, Reant P, Lafitte M, et al. Global and regional myocardial function quantification by two-dimensional strain: application in hypertrophic cardiomyopathy. J Am Coll Cardiol 2006; 47: 1175-1181.
30. Leitman M, Lysyansky P, Sidenko S, et al. Two-dimensional strain-a novel software for real-time quantitative echocardiographic assessment of myocardial function. J Am Soc Echocardiogr 2004; 17: 1021-1029.
31. Marwick TH, Leano RL, Brown J, et al. Myocardial strain measurement with 2-dimensional speckle-tracking echocardiography: definition of normal range. JACC Cardiovasc Imaging 2009; 2: 80-84.
32. Morrison LK, Harrison A, Krishnaswamy P, Kazanegra R, Clopton P, Maisel A. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol 2002; 39: 202-209.
33. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol 2007; 50: 2357-2368.
34. Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370: 2011-2019.
35. Orphanos GS, Ioannidis GN, Ardavanis AG. Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncol 2009; 48: 964-970.